<DOC>
	<DOCNO>NCT02484807</DOCNO>
	<brief_summary>The development disease-targeted medication treatment pulmonary arterial hypertension ( PAH ) significantly improve within last year , lead development 10 approve agent . Combination treatment Endothelin-Receptor-Antagonists ( ERA ) Phosphodiesterase-Type-5-Inibitors ( PDE-5-Inhibitor ) become increasingly important treatment PAH . In recent press release , result AMBITION study report upfront combination treatment immediately diagnosis lead delayed disease progression [ 4 ] . Thus , question clinically relevant pharmaco-dynamic drug-drug interaction rise interest .</brief_summary>
	<brief_title>Effect Pharmacologic Interaction Between ERAs PDE-5 Inhibitors Medication Serum Levels Clinical Disease Status Patients With PAH</brief_title>
	<detailed_description>Mechanisms action Three ERAs approve treatment PAH include dual inhibitor Bosentan Macitentan selective Endothelin Receptor type A inhibitor ( ETA-Inhibitor ) Ambrisentan . The dual antagonist inhibit ETA- type B ( ETB ) -receptor , selective antagonist affect ETA-receptor [ 2 ] . The physiologic ligand receptor Endothelin-1 , bind ETA-receptor cause vasoconstriction proliferation vascular smooth muscle cell . The bind ETB-receptor lead endogenous production NO prostacyclin endothelial cell . PDE-5-Inhibitors include two substance Sildenafil Tadalafil . They inhibit degradation cyclic guanosine monophosphate ( cGMPs ) , trigger vasodilative effect endothelial NO . Interaction There evidence pharmacokinetic interaction ( inhibition / induction critical target drug metabolism drug distribution ) substance class : PDE-5-Inhibitors Sildenafil Tadalafil mainly eliminate liver hepatic enzyme Cytochrom-P450-Oxygenase type 3A4 ( CYP3A4 ) . The dual inhibitor Bosentan substrate inductor Cytochrom-P450-Oxydase type 3A4 type 2C9 [ 5,6 ] . It already show vivo-study , simultaneous application PDE-5-Inhibitors Bosentan lead systemic reduction PDE-5-Inhibitor concentration 40 % , due CYP3A4-inducing effect Bosentan [ 5 ] . Sildenafil , contrast , lead decrease degradation Bosentan liver approximately 50 % increase plasma leves . An anticipated result , especially high dosage Sildenafil apply , accumulation Bosentan reduction Sildenafil level . A recent vitro-study show Tadalafil may also serve CYP3A4-inductor , effect detect Sildenafil [ 7 ] . In contrast Macitentan approve 2013 , clinically relevant CYP3A4-inducing effect . [ 8 ] . The vitro-study also detect interaction ERAs PDE-5-Inhibitors . Both PDE-5-Inhibitors Sildenafil Tadalafil affect transport molecule organic anion transport polypeptide ( OATPs ) , responsible hepatocellular intake dual ERA Bosentan . They also mild effect intake Ambrisentan . Sildenafil potent inhibitor OATPs , whereas Tadalafil show minor inhibition OATPs [ 7 ] . Both Sildenafil Tadalafil significantly reduce intracellular concentration Bosentan liver , lead reduce degradation Bosentan . For Ambrisentan effect seem less pronounced [ 7 ] . Consequently , mechanisms action lead high ERA-levels decrease PDE-5-Inhibitor plasma concentration patient receive combination treatment . The distinct interaction expect combination Sildenafil ( PDE-5-Inhibitor ) Bosentan ( ERA ) . Up , prevalence role pharmacokinetic interaction clinical status progression disease clear . Respective combination treatment investigate healthy male volunteer far [ 5,9 ] . Literature 1 . Galie N , Hoeper MM , Humbert M , et al . Guidelines diagnosis treatment pulmonary hypertension . The task force diagnosis treatment pulmonary hypertension European Society Cardiology ( ESC ) European Respiratory Society ( ERS ) , endorse International Society Heart Lung Transplantation ( ISHLT ) . Eur Respir J 2009 ; 34:1219-63 . 2 . Humbert M , Sitbon O , Simonneau G. Treatment pulmonary arterial hypertension . The New England journal medicine 2004 ; 351:1425-36 . 3 . Voelkel NF , Gomez-Arroyo J , Abbate A , Bogaard HJ , Nicolls MR. Pathobiology pulmonary arterial hypertension right ventricular failure . Eur Respir J 2012 ; 40:1555-65 . 4 . First-Line Combination Ambrisentan Tadalafil Reduces Risk Clinical Failure Compared Monotherapy Pulmonary Arterial Hypertension Outcomes Study . Gilead Sciences Inc. , 2014 . ( Accessed 2014-10-13 , 2014 , http : //www.gilead.com/news/press-releases/2014/9/firstline-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study . ) 5 . Wrishko RE , Dingemanse J , Yu A , Darstein C , Phillips DL , Mitchell MI . Pharmacokinetic interaction tadalafil bosentan healthy male subject . Journal clinical pharmacology 2008 ; 48:610-8 . 6 . Paul GA , Gibbs JS , Boobis AR , Abbas A , Wilkins MR. Bosentan decrease plasma concentration sildenafil coprescribed pulmonary hypertension . British journal clinical pharmacology 2005 ; 60:107-12 . 7 . Weiss J , Theile D , Spalwisz A , Burhenne J , Riedel KD , Haefeli WE . Influence sildenafil tadalafil enzyme- transporter-inducing effect bosentan ambrisentan LS180 cell . Biochemical pharmacology 2013 ; 85:265-73 . 8 . Weiss J , Theile D , Ruppell MA , Speck T , Spalwisz A , Haefeli WE . Interaction profile macitentan , new non-selective endothelin-1 receptor antagonist , vitro . European journal pharmacology 2013 ; 701:168-75 . 9 . Burgess G , Hoogkamer H , Collings L , Dingemanse J . Mutual pharmacokinetic interaction steady-state bosentan sildenafil . European journal clinical pharmacology 2008 ; 64:43-50 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Men woman ≥ 18 year old 2 . Diagnosis PAH accord ESC/ERSguidelines : patient manifest pulmonary arterial hypertension , mean pulmonary arterial pressure ≥25mmHg , measure right heart catheterization . 3 . Combination treatment ERA ( Bosentan , Ambrisentan Macitentan ) PDE5Inhibitor ( Sildenafil Tadalafil ) 3 month . 1 . Underage patient 2 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>